The role of the tissue factor-thrombin pathway in cardiac ischemia-reperfusion injury

Seminars in Vascular Medicine

Volumn 3, Issue 2, 2003, Pages 193-198

  Mackman, Nigel ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Cardiac ischemia reperfusion injury; Coagulation; Protease activated receptor; Tissue factor

Indexed keywords

ACTIVE SITE INACTIVATED RECOMBINANT BLOOD CLOTTING FACTOR 7A; ANCROD; AUTACOID; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 5A; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING INHIBITOR; CELL ADHESION MOLECULE; CHEMOKINE; COMPLEMENT; CYTOKINE; FIBRIN; FIBRINOGEN; FIBRINOLYTIC AGENT; HIRUDIN; LEPIRUDIN; MESSENGER RNA; MONOCLONAL ANTIBODY; OXYGEN RADICAL; PROTEINASE; PROTEINASE ACTIVATED RECEPTOR 1; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBIN; THROMBIN INHIBITOR; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; BLOOD CLOTTING; CELL ACTIVATION; CELL DEATH; CELL TYPE; COMPLEMENT ACTIVATION; COMPLEX FORMATION; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; CYTOKINE PRODUCTION; DISEASE MODEL; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; ENDOTHELIUM CELL; FIBRIN DEPOSITION; GENE EXPRESSION; HEART INFARCTION SIZE; HEART MUSCLE BLOOD FLOW; HEART MUSCLE CELL; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; NEUTROPHIL CHEMOTAXIS; NONHUMAN; NORTHERN BLOTTING; PATHOPHYSIOLOGY; PROTEIN BINDING; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN PROTEIN INTERACTION; RABBIT; REPERFUSION INJURY; SIGNAL TRANSDUCTION; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOGENESIS; THROMBOSIS; VASCULAR ENDOTHELIUM;

ANIMALS; BLOOD COAGULATION; FACTOR VIIIA; FIBRINOGEN; HUMANS; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; RABBITS; RECEPTOR, PAR-1; THROMBIN; THROMBOPLASTIN;

EID: 0042474500     PISSN: 15289648     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-40677     Document Type: Article

References (38)

1. Bolli R. Oxygen-derived free radicals and myocardial reperfusion injury: an overview. Cardiovasc Drugs Ther 1991;5:249-268
2. Homeister JW, Satoh P, Kilgore KS, Luchessi BR. Effects of complement activation in the isolated heart. Role of the terminal complement components. Circ Res 1992;71:303-319
3. Entman ML, Smith WC. Postreperfusion inflammation: a model for reaction to injury. Cardiovasc Dis 1994;28:1301-1311
4. Jordan JE, Zhao ZQ, Vinten-Johansen J. The role of neutrophils in myocardial ischemia-reperfusion injury. Cardiovasc Res 1999;43:860-878
5. Entman ML, Michael L, Rossen RD, et al. Inflammation in the course of early myocardial ischemia. FASEB J 1991;5:2529-2537
6. Herskowitz A, Choi S, Ansari AA, Wesselingh S. Cytokine mRNA expression in postischemic/reperfused myocardium. Am J Pathol 1995;146(2):419-428
7. Matsumura K, Jeremy RW, Schaper J, Becker LC. Progression of myocardial necrosis during reperfusion of ischemic myocardium. Circulation 1998;97:795-804
8. Ma XL, Lefer DJ, Lefer AM, Rothlein R. Coronary endothelial and cardiac protective effects of a monoclonal antibody to intercellular adhesion molecule-1 in myocardial ischemia and reperfusion. Circulation 1992;86(3):937-946
9. Ma XL, Tsao PS, Lefer AM. Antibody to CD-18 exerts endothelial and cardiac protective effects in myocardial ischemia and reperfusion. J Clin Invest 1991;88(4):1237-1243
10. Boyle EM Jr, Kovacich JC, Hébert CA, et al. inhibition of interleukin-8 blocks myocardial ischemia-reperfusion injury. J Thorac Cardiovasc Surg 1998;116:114-121
11. Harlan JM, Winn RK. Leukocyte-endothelial interactions: clinical trials of anti-adhesion therapy. Crit Care Med 2002;30:S214-S219
12. Edgington TS, Mackman N, Brand K, Ruf W. The structural biology of expression and function of tissue factor. Thromb Haemost 1991;66:67-79
13. Davie EW, Fujikawa K, Kisiel W. The coagulation cascade: initiation, maintenance, and regulation. Biochemistry 1991;30:10363-10370
14. Drake TA, Morrissey JH, Edgington TS. Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis. Am J Pathol 1989;134:1087-1097
15. Fleck RA, Rao LVM, Rapaport SI, Varki N. Localization of human tissue factor antigen by immunostaining with monospecific, polyclonal anti-human tissue factor antibody. Thromb Res 1990;57:765-781
16. Coughlin SR. Thrombin signalling and protease-activated receptors. Nature 2000;407:258-264
17. Déry O, Corvera CU, Steinhoff M, Bunnett NW. Proteinase-activated receptors: novel mechanisms of signaling by serine proteases. Am J Physiol 1998;274:C1429-C1452
18. Golino P, Ragni M, Cirillo P, et al. Effects of tissue factor induced by oxygen free radicals on coronary flow during reperfusion. Nature Med 1996;2:35-40
19. Erlich JH, Boyle EM Jr, Labriola J, et al. Inhibition of the tissue factor-thrombin pathway limits infarct size after myocardial ischemia-reperfusion injury by reducing inflammation. Am J Pathol 2000;157:1849-1862
20. Mrak RE, Murphy ML, Peng CF, Straub KD. Microvasculature sparing with controlled reperfusion of ischemic myocardium. Am J Cardiovasc Pathol 1990;3:253-258
21. Hui KY, Haber E, Matsueda GR. Monoclonal antibodies to a synthetic fibrin-like peptide bind to human fibrin but not fibrinogen. Science 1983;222:1129-1132
22. Armaganian L, Kam G, Eisenberg PR, Schechtman KB, Abendschein DR. Role of tissue factor-mediated coagulation in ischemia/reperfusion-induced injury of Langendorf-perfused rabbit hearts. Coron Artery Dis 2000;11:481-487
23. Golino P, Ragni M, Cirillo P, et al. Recombinant human, active site-blocked factor VII reduces infarct size and the NO-reflow phenomenon in a rabbit model of myocardial ischemia and reperfusion. Am J Physiol Heart Circ Physiol 2000;278: H1507-H1516
24. Gertz SD, Fallon JT, Gallo R, et al. Hirudin reduces tissue factor expression in neointima after balloon injury in rabbit femoral and porcine coronary arteries. Circulation 1998;98:580-587
25. Hatton MWC, Ross B, Soutward SMR, DeReske M, Richardson M. Pretreatment of rabbits with either hirudin, ancrod, or warfarin significantly reduces the immediate uptake of fibrinogen and platelets by the deendothelialized aorta wall after balloon-catheter injury in vivo. Arterioscler Thromb Vasc Biol 1998;18:816-824
26. Kupatt C, Habazettl H, Hanusch P, et al. c7E3Fab reduces postischemic leukocyte-thrombocyte interaction mediated by fibrinogen. Implications for myocardial reperfusion injury. Arterioscler Thromb Vasc Biol 2000;20:2226-2232
27. Cunningham MA, Rondeau E, Chen X, Coughlin SR, Holdsworth SR, Tipping PG. Protease-activated receptor 1 mediates thrombin-dependent, cell-mediated renal inflammation in crescentic glomerulonephritis. J Exp Med 2000;191:455-461
28. Broze GJ Jr. Tissue factor pathway inhibitor. Thromb Haemost 1995;74(1):90-93
29. Presta L, Sims P, Meng YG, et al. Generation of a humanized, high affinity anti-tissue factor antibody for use as a novel antithrombotic therapeutic. Thromb Haemost 2001;85:379-389
30. Kelley RF, Refino CJ, O'Connell MP, et al. A soluble tissue factor mutant is a selective anticoagulant and antithrombotic agent. Blood 1997;89:3219-3227
31. Nicolaisen EM, Kristensen H, Kristensen A, Hedner U. Evaluation of potential antigenicity of active-site-inhibited recombinant human FVIIa (FFR-rFVIIa) in an immunetolerant rat model. Thromb Haemost 2002;87:836-839
32. Lee A, Agnelli G, Buller H, et al. Dose-response study of recombinant factor VIIa/tissue factor inhibitor recombinant nematode anticoagulant protein c2 in prevention of postoperative venous thiomboembolism in patients undergoing total knee replacement. Circulation 2001;104:74-78
33. Jang I-K, Gold HK, Leinbach RC, Fallon JT, Collen D, Wilcox JN. Antithrombotic effect of a monoclonal antibody against tissue factor in a rabbit model of platelet-mediated arterial thrombosis. Arterioscler Thromb 1992;12:948-954
34. Pawashe AB, Golino P, Ambrosio G, et al. A monoclonal antibody against rabbit tissue factor inhibits thrombus formation in stenotic injured rabbit carotid arteries. Circ Res 1994;74:56-63
35. Ragni M, Cirillo P, Pascucci I, et al. Monoclonal antibody against tissue factor shortens tissue plasminogen activator lysis time and prevents reocclusion in a rabbit model of carotid artery thrombosis. Circulation 1996;93:1913-1918
36. Jang Y, Guzman LA, Lincoff AM, et al. Influence of blockade at specific levels of the coagulation cascade on restenosis in a rabbit atherosclerotic femoral artery injury model. Circulation 1995;92(10):3041-3050
37. Oltrona L, Speidel CM, Recchia D, Wickline SA, Eisenberg PR, Abendschein DR. Inhibition of tissue factor-mediated coagulation markedly attenuates stenosis after balloon-induced arterial injury in minipigs. Circulation 1997;96:646-652
38. Abraham E, Reinhart K, Svoboda P, et al. Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study. Crit Care Med 2001;29:2081-2089